ML Laboratories’ share price received a boost this morning after the firm responded to press speculation that it was in discussions, which could ultimately lead to the company making an acquisition.

In a brief press release, the UK firm said it was holding talks with a view to buying “a profitable company involved in the development of inhaled therapies.” The company said it would make a further announcement “in due course.”

Earlier this year, ML’s licensing partner won two marketing approvals in its first European markets for its dry powder inhaler, Clickhaler, for use with budesonide and formoterol respectively – two widely-prescribed asthma therapies.